The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival
Alexey V. Danilov,
Ian W. Flinn,
Matthew S. Davids,
Beth Gregory,
Ohad Bentur,
David Sidransky,
Jennifer R. Brown
Affiliations
Alexey V. Danilov
City of Hope National Medical Center, Duarte, CA
Ian W. Flinn
Tennessee Oncology, Nashville, TN
Matthew S. Davids
CLL Center, Dana-Farber Cancer Institute, Boston, MA
Beth Gregory
Secura Bio, Inc., Las Vegas, NV
Ohad Bentur
Secura Bio, Inc., Las Vegas, NV
David Sidransky
Johns Hopkins University, Baltimore, MD
Jennifer R. Brown
CLL Center, Dana-Farber Cancer Institute, Boston, MA
